POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Myelofibrosis drug combo trial halted early
Disease control TerminatedThis study tested whether adding the drug parsaclisib to the standard treatment ruxolitinib could help people with myelofibrosis, a rare bone marrow cancer. It included 252 adults with an enlarged spleen and symptoms. The trial was terminated early, so final results are not avail…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
New combo therapy aims to shrink spleens and ease symptoms in myelofibrosis patients
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard treatment ruxolitinib helps people with myelofibrosis whose spleens and symptoms haven't improved enough on ruxolitinib alone. About 177 adults with different types of myelofibrosis took part. The …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 08:26 UTC